References
- Archelos J J, Trotter J, Previtali S, Weissbrich B, Toyka K V, Hartung H P. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol 1988; 43: 14–24
- Becker K G, Mattson D H, Powers J M, Gado A M, Biddison W E. Analysis of a sequenced cDNA library from multiple sclerosis lesions. J Neuroimmunol 1997; 77: 27–38
- Comabella M, Balashov K, Issazadeh S, Smith D, Weiner H L, Khoury S J. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1989; 102: 671–678
- Ebers G C, Sadovnick A D, Risch N J, the Canadian Collaborative Study Group. A genetic basis for familiar aggregation in multiple sclerosis. Nature 1995; 377: 150–151
- Ebers G C, Kukay K, Bulman D E, Sadovnick A D, Rice G, Anderson C, et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13: 472–476
- Filippi M, Rocca M A, Martino G, Horsfield M A, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43: 809–814
- Hemmer B, Fleckenstein B T, Vergelli M, Jung G, McFarland H, Martin R, Weismuller K H. Identification of high potency microbial and self ligands for a human autoreactive class-II restricted T cell clone. J Exp Med 1997; 185: 1651–1659
- Issazadeh S, Navikas V, Schaub M, Sayegh M, Khoury S. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J Immunol 1998; 161: 1104–1112
- Katz D, Taubenberger J K, Canella B, McFarlin D E, Raine C S, McFarland H F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661–669
- Kermode A G, Thompson A J, Tofts P, MacManus D G, Kendall B E, Kinsley D P E, Moseley I F, Rudge P, McDonald W I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990; 113: 1477–1489
- Lublin F D, Whitaker J N, Eidelman B H, Miller A E, Arnason B G W, Burks J S. Management of patients receiving interferon beta-lb for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12–18
- Martin R, Whitekar J N, Rhame L, Goodin R R, McFarland H F. Citrulline-containing myelin basic protein is recognized by T-cell lines derived from multiple sclerosis patients and healthy individuals. Neurology 1994; 44: 123–129
- Richert J R, Robinson E D, Deibler G E, Martenson R E, Dragovic L J, Kies M W. Evidence for multiple human T cell recognition sites on myelin basic protein. J Neuroimmunol 1989; 23: 55–66
- Silver N C, Lai M, Symms M R, Barker G J, McDonald W I, Miller D H. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 1998; 51: 758–764
- Sriram S, Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology 1997; 48: 464–470
- Trapp B D, Peterson J, Ransohoff R M, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Eng J Med 1998; 338: 278–285
- Yong V W, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanism of action. Neurology 1998; 51: 682–689
- Voskuhl R R, McFarlin D E, Tranquill L R, Deibler G, Stone R, Maloni H, McFarland H F. A novel candidate autoantigen in a multiplex family with multiple sclerosis: prevalence of T-lymphocytes for an MBP epitope unique to myelination. J Neuroimmunol 1993; 46: 137–144
- Wood D D, Bilbao J M, O'Connors P, Moscarello M A. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996; 40: 18–24